Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | XDH | P47989 | 4/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.55 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | DAO | P14920 | 2/20 | 0.52 |
| ▸ | CDC7 | O00311 | 1/20 | 0.52 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29787350 | 0.82 | ALDH1A1 (0.69) | CYP1A2CYP3A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL5998047 | 0.79 | XDH (0.52) | CYP1A2CYP3A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL5084818 | 0.76 | PNP (0.58) | DAO | |
| SCHEMBL11135472 | 0.73 | XDH (0.62) | CYP1A2CYP3A4CYP2C19ALDH1A1LMNA | |
| SCHEMBL3433603 | 0.73 | TSHR (0.52) | LMNAMAPK1SMN1; SMN2TP53NPC1 | |
| SCHEMBL18251 | 0.73 | PNP (0.62) | XDH | |
| SCHEMBL7765338 | 0.72 | PNP (0.46) | CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1394088 | 0.72 | PNP (0.61) | XDH | |
| Guanine SCHEMBL1394087 | 0.72 | PNP (0.68) | CYP1A2CYP3A4CYP2C19LMNAPOLB | |
| Hypoxanthine SCHEMBL5677623 | 0.71 | ALDH1A1 (0.64) | CYP1A2CYP3A4CYP2C19ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680270-B2 | Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| EP-2086546-B1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS INC (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2086546-A2 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | Viamet Pharmaceuticals, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008064311-A2 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| EP-1257555-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | NQO1, SOD1, MDH2 | CYP1A2 863/4885CYP3A4 1878/4885CYP2C19 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.